Arcellx. has filed a patent for D domain containing polypeptides that bind specific targets of interest. The patent also includes nucleic acids, vectors, and host cells encoding these polypeptides. The invention has potential applications in diagnostics and therapeutics. Additionally, the patent covers multi-functional chimeric antigen receptor (CAR)-based compositions and Adapters that can modulate immune responses to target cells. The claim specifically describes a polypeptide that binds CD 123 with a specific amino acid sequence. GlobalData’s report on Arcellx gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights Arcellx Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Arcellx, Peptide pharmacophores was a key innovation area identified from patents. Arcellx's grant share as of September 2023 was 31%. Grant share is based on the ratio of number of grants to total number of patents.

The patent is filed for a polypeptide that binds cd 123

Source: United States Patent and Trademark Office (USPTO). Credit: Arcellx Inc

A recently filed patent (Publication Number: US20230250185A1) describes a novel polypeptide called AD Domain target binding domain polypeptide that specifically binds CD 123. This polypeptide has a specific amino acid sequence and can be fused to a heterologous polypeptide. The heterologous polypeptide can be a full-length antibody or fragment, an Fc domain, a transmembrane domain, a membrane associating domain, human serum albumin or a fragment thereof, AFP or a fragment thereof, AFP p26 or a fragment thereof, or the extracellular domain of a receptor or a fragment thereof. The polypeptide can also be labeled or conjugated to a therapeutic or cytotoxic agent.

The patent also describes a chimeric antigen receptor (CAR) that includes the target binding domain of the AD Domain polypeptide, which specifically binds CD 123. The CAR can further include a transmembrane domain and an intracellular signaling domain. The transmembrane domain can be CD8a, 41BB, or CD28, and the intracellular signaling domain can be a domain of a human T cell receptor alpha, beta, or zeta chain, a human 41BB domain, a human CD28 domain, or any combination thereof. Additionally, the intracellular signaling domain can include the intracellular domain of a costimulatory molecule such as CD27, CD28, 41BB, OX40, CD30, CD40, PD1, lymphocyte function-associated antigen-1 (LFA-1), CD2, CD7, LIGHT, NKG2C, NKG2D, B7-H3, a ligand that specifically binds with CD83, or any combination thereof.

The patent also covers an Adapter that includes the D domain target binding domain that specifically binds CD123 and an antigenic determinant (AD). The AD can be an AFP p26 polypeptide with a specific amino acid sequence. The Adapter can have a single D domain that specifically binds CD123 or two D domains that specifically bind CD123.

The patent further includes methods of producing the polypeptide and CAR, as well as methods of delivering an immune response to a target cell or killing a target cell using the CAR and Adapter. The methods involve contacting the target cell with a cell expressing the CAR and/or the Adapter. The target cell can be a cancer cell, specifically acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome cell. The methods can be used in patients by administering a cell expressing the CAR or an Adapter that specifically binds CD123 and an AFP p26 AD.

Overall, this patent describes novel polypeptides, chimeric antigen receptors, Adapters, and methods for delivering an immune response or treating cancer using these components. These inventions have potential applications in the field of immunotherapy and targeted cancer treatment.

To know more about GlobalData’s detailed insights on Arcellx, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies